Prothena (NASDAQ: PRTA) CEO exercises 84,000 RSUs, disposes 84,000 shares

Rhea-AI Filing Summary

PROTHENA CORP PUBLIC LTD CO President and CEO Gene G. Kinney exercised 84,000 restricted stock units into the same number of ordinary shares on July 28, 2026. These units were part of a 140,000 RSU grant awarded on July 28, 2025. On the same date, he disposed 84,000 ordinary shares back to the issuer at $8.56 per share. According to the award terms, the remaining 56,000 RSUs from that grant are still subject to future vesting.

Insider Trade Summary

84,000 shares exercised/converted

Exercise 3 txns

Insider Kinney Gene G.

Role President and CEO

Type	Security	Shares	Price	Value
Exercise	Restricted Stock Units F2, F1, F3	84,000	$0.00	$0.00
Exercise	Ordinary Shares, par value $0.01 per share F1	84,000	--	--
Disposition	Ordinary Shares, par value $0.01 per share	84,000	$8.56	$719K

Holdings After Transaction: Restricted Stock Units — 0 shares (Direct); Ordinary Shares, par value $0.01 per share — 68,793 shares (Direct)

Footnotes (3)

1. F1. Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting.
2. F2. These RSUs reported in Table II were granted to the Reporting Person on July 28, 2025 as part of an aggregate award of 140,000 RSUs and initially reported in Table I of the Form 4 filed on July 30, 2025, because they were solely settleable in shares at the time of grant. These RSUs are being moved to Table II as of this Form 4.
3. F3. These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 140,000 RSUs reported in Table I (56,000 RSUs) are subject to vesting.

Key Figures

RSUs exercised: 84,000 units Ordinary shares acquired on exercise: 84,000 shares Shares disposed to issuer: 84,000 shares +3 more

6 metrics

RSUs exercised 84,000 units Restricted stock units converted to ordinary shares on July 28, 2026

Ordinary shares acquired on exercise 84,000 shares Shares received upon RSU conversion by Gene G. Kinney

Shares disposed to issuer 84,000 shares Ordinary shares disposed back to issuer on July 28, 2026

Disposition price $8.56 per share Price for 84,000 ordinary shares disposed to issuer

Original RSU grant size 140,000 RSUs Aggregate RSU award granted to Gene G. Kinney on July 28, 2025

RSUs remaining subject to vesting 56,000 RSUs Unvested portion of the 140,000-unit RSU grant after July 28, 2026

Key Terms

Restricted Stock Units, Table II, disposition to issuer

3 terms

Restricted Stock Units financial

"Each restricted stock unit ("RSU") represents the contingent right to receive one share"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Table II regulatory

"These RSUs reported in Table II were granted to the Reporting Person on July 28, 2025"

disposition to issuer financial

"Ordinary Shares, par value $0.01 per share ... transaction code "D" ... Disposition to issuer"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 07/30/2026 - 08:32 PM Accepted by SEC EDGAR 07/30/2026 - 08:31 PM Learn about SEC filing dates

FAQ

What insider stock transaction did PRTA CEO Gene G. Kinney report?

Gene G. Kinney reported exercising 84,000 RSUs into ordinary shares and, on the same date, disposing 84,000 ordinary shares back to Prothena at $8.56 per share, according to the Form 4 disclosure.

How many restricted stock units did PRTA grant that relate to this CEO transaction?

The exercised 84,000 RSUs were part of an aggregate grant of 140,000 RSUs awarded to Gene G. Kinney on July 28, 2025, as described in the Form 4 footnotes.

What portion of PRTA CEO Gene G. Kinney’s RSU award remains unvested?

From the original 140,000 RSU grant, 56,000 RSUs remain subject to vesting after 84,000 units vested and were exercised as of July 28, 2026, per the award’s vesting terms.

At what price were Gene G. Kinney’s PRTA shares disposed to the issuer?

The 84,000 ordinary shares disposed by Gene G. Kinney were transferred back to the issuer at a price of $8.56 per share, as reported in the Form 4 transaction table.

Were PRTA CEO Gene G. Kinney’s RSUs fully vested at the time of exercise?

The 84,000 RSUs reported in this transaction were fully vested as of July 28, 2026, the one-year anniversary of the July 28, 2025 grant date, according to the footnotes.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kinney Gene G.

(Last) (First) (Middle)

C/O PROTHENA BIOSCIENCES INC

1800 SIERRA POINT PARKWAY

(Street)

BRISBANE CALIFORNIA 94005

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
PROTHENA CORP PUBLIC LTD CO [ PRTA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares, par value $0.01 per share	07/28/2026		M		84,000	A	(1)	152,793	D
Ordinary Shares, par value $0.01 per share	07/28/2026		D		84,000	D	$8.56	68,793	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units(2)	(1)	07/28/2026		M			84,000	(3)	(3)	Ordinary Shares	84,000	$0	0	D

Explanation of Responses:

1. Each restricted stock unit ("RSU") represents the contingent right to receive one share of the Issuer's Ordinary Shares upon vesting.

2. These RSUs reported in Table II were granted to the Reporting Person on July 28, 2025 as part of an aggregate award of 140,000 RSUs and initially reported in Table I of the Form 4 filed on July 30, 2025, because they were solely settleable in shares at the time of grant. These RSUs are being moved to Table II as of this Form 4.

3. These RSUs reported in Table II are fully vested as of July 28, 2026 (the one-year anniversary of the grant date). The remainder of the 140,000 RSUs reported in Table I (56,000 RSUs) are subject to vesting.

	/s/ Michael J. Isaacs, as Attorney-in-Fact for Gene G. Kinney	07/30/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)